An evaluation of dapsone gel 5% in the treatment of acne vulgaris.
BACKGROUND
Oral dapsone has been available for over 60 years. Its first clinical use was discovered in 1945, when it was found to be efficacious in inhibiting the progression of leprosy. The combined antibacterial and anti-inflammatory pharmacologic activities of dapsone have made it a widely investigated drug, particularly for use in refractory and unusual dermatologic conditions. However, the possibility of significant hematological side effects, even at low doses, has limited its use. Currently, oral dapsone has FDA approval for the treatment of leprosy and dermatitis herpetiformis. The potential of oral dapsone to treat acne vulgaris is well established, but the risks of serious side effects have made it an undesirable drug for use in the relatively healthy acne population. Recently, a topical formulation of dapsone (Aczone, Allergan, Inc., Irvine, CA, USA) has been approved by the FDA for the treatment of acne vulgaris.


OBJECTIVE
The aims of this study were to review the published literature on dapsone pharmacology and pharmacokinetics, and to evaluate the gel's efficacy and safety in treating acne vulgaris, and finally to provide personal insight into its future as a topical agent for acne vulgaris.


CONCLUSIONS
Clinical studies indicate dapsone gel 5% is effective in treating mild to moderately severe acne. It is well tolerated, with pharmacokinetic evidence indicating topical dosing in comparison to oral administration significantly reduces systemic concentrations of the drug, and therefore risk of serious side effects. Data suggests that dapsone gel 5% has the potential to become an established topical drug for the treatment of acne vulgaris. However, studies comparing the clinical effectiveness of the dapsone gel 5% to other available topical antiacne drugs are needed as are studies accessing its usefulness and safety when combined with other acne pharmaceuticals.
Pickert
Amanda
A
Texas Tech University Health Sciences Center Lubbock, TX, USA.
Raimer
Sharon
S
D000152:Acne Vulgaris / Q000188:drug therapy* / Q000378:metabolism; D000287:Administration, Topical; D000818:Animals; D003622:Dapsone / Q000008:administration & dosage* / Q000737:chemistry / Q000493:pharmacokinetics; D004341:Drug Evaluation / Q000379:methods; D005782:Gels; D006801:Humans; D016896:Treatment Outcome
D005782:Gels; D003622:Dapsone